John Garner, MD
Clinical Cardiac Electrophysiology · Springfield, MONPI 1093861601
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Boston Scientific at 41.6% of the total. Reporting peaked in 2024 at $16,770 and has fallen 63.2% since, to $6,174 in 2025.
Across 266 payments — averaging $133.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Biosense Webster, Inc.$13K
- Medtronic$4K
- Abbott$780
- Pfizer$519
- Kestra Medical Technology Services, Inc.$393
- plus $2K from 21 others
Across 89 payments — averaging $1712.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$152K
What the payments were for
- Consulting fees$19,27554%
- Travel & lodging$6,57019%
- Food & beverage$9,63527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 60 | $14,758 |
| Biosense Webster, Inc. | 43 | $13,336 |
| Medtronic(2 entities) | 40 | $4,185 |
| Abbott | 18 | $780 |
| Pfizer | 48 | $519 |
| Kestra Medical Technology Services, Inc. | 16 | $393 |
| Endologix LLC | 2 | $318 |
| Boehringer Ingelheim | 4 | $139 |
| Biotronik Inc. | 2 | $132 |
| Medline Industries LP | 2 | $120 |
| Daiichi Sankyo Inc. | 1 | $99 |
| Chiesi USA, Inc. | 3 | $87 |
| Edwards Lifesciences | 3 | $86 |
| Terumo Medical Corporation | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Shockwave Medical, Inc | 1 | $57 |
| AstraZeneca | 3 | $44 |
| Abiomed | 1 | $37 |
| Acera Surgical, Inc. | 2 | $34 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $34 |
| Amgen | 2 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Baxter Healthcare | 1 | $27 |
| W. L. Gore & Associates, Inc. | 1 | $26 |
| Stryker | 1 | $20 |
| Heartflow, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$6,859
- GENERAL - THERAPIES$6,660
- Carto 3 System$2,550
- Carto Smarttouch$2,550
- Carto CFAE$2,550
- CartoSound$2,550
- Micra$379
- OCTARAY MAPPING CATHETER$292
- Alto Abdominal Stent Graft System$259
- Reveal LINQ$216
- CoreValve Evolut$209
- COBALT DR MRI SURESCAN$142
- ENSITE$141
- LINQ II$135
- Assurity Pacemaker$123
- QDOT MICRO$122
- Confirm Rx$120
- WATCHMAN FLX$115
- Advisa$112
- NUVISION ICE CATHETER$111
How this compares
$35,479 in reported general payments places this provider in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
See all clinical cardiac electrophysiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 620 | $475,643 |
| XareltoRivaroxaban | 189 | $166,324 |
| EntrestoSacubitril/Valsartan | 98 | $80,754 |
| FarxigaDapagliflozin Propanediol | 35 | $35,826 |
| JardianceEmpagliflozin | 34 | $25,420 |
| MultaqDronedarone Hcl | 11 | $8,045 |
| Flecainide Acetate | 172 | $7,340 |
| Dofetilide | 42 | $5,035 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $2,816 |
| Metoprolol Succinate | 256 | $2,498 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 110 | $2,372 |
| Warfarin Sodium | 267 | $1,692 |
| Eplerenone | 25 | $1,420 |
| Sotalol AfSotalol Hcl | 35 | $1,396 |
| Torsemide | 61 | $1,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $519 | $475,643620 claims |
| AstraZenecaFarxiga | $44 | $35,82635 claims |
| Boehringer IngelheimJardiance | $139 | $25,42034 claims |
| Sanofi-aventis U.S. LLCMultaq | $28 | $8,04511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
Other clinical cardiac electrophysiology in Springfield
- Shang-Chiun LeeSpringfield$50K
- Sunthosh ParvathaneniSpringfield$43K
- Kamal CheemaSpringfield$30K
- Indrajeet MahataSpringfield$24K
- Jian Liang TanSpringfield$13K
- Scott FerreiraSpringfield$6K
- Stanley WigginsSpringfield$5K
- Phillip CuculichSaint Louis$473K
- Sanjaya GuptaKansas City$316K
- Daniel CooperSaint Louis$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.